Immunologic checkpoint blockade in lung cancer

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 402-417

  Reck, Martin ^a   Paz Ares, Luis ^b  

^a Airway Research Center North (ARCN)   (Germany)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; BMS 936559; BMS 986016; CP 870893; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 RECEPTOR; DURVALUMAB; HYBRID PROTEIN; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LAG 3 PROTEIN; LIRILUMAB; LYMPHOCYTE ANTIGEN RECEPTOR; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; TICILIMUMAB; TRX 518; UNCLASSIFIED DRUG; URELUMAB; IMMUNOLOGIC FACTOR;

ARTICLE; BRONCHOSCOPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; LAVAGE; LONG TERM SURVIVAL; LUNG CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR IMMUNOLOGY; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; LUNG NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; LUNG NEOPLASMS;

EID: 84929208731     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.013     Document Type: Review

References (103)

1. J. Ferlay, H.-R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. http://www.wcrf.org/cancer-statistics/world-cancer-statistics.php. 2012; Available at: http://www.wcrf.org/cancer-statistics/world-cancer-statistics.php. Accessed March 2014.
3. Surveillance, Epidemiology, and End Results [SEER] incidence and National Center for Health Statistics [NHCS] mortality statistics. Available at: http://www.cancer.gov/cancertopics/types/lung/cancer-survival-prognosis. Last accessed 4 August 2014.
4. R. De Angelis, M. Sant, and M.P. Coleman Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE - 5-a population-based study Lancet Oncol 15 1 2014 23 34
5. P. Goldstraw, J. Crowley, and K. Chansky The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 8 2007 706 714
6. D.N. Carney Lung cancer - time to move on from chemotherapy N Engl J Med 346 2002 126 128
7. S. Cardarella, T.M. Ortiz, and V.A. Joshi The introduction of systematic genomic testing for patients with non-small-cell lung cancer J Thorac Oncol 7 2012 1767 1774
8. D.M. Pardoll Does the immune system see tumors as foreign or self? Annu Rev Immunol 21 2003 807 839
9. G.E. Holt, E.R. Podack, and L.E. Raez Immunotherapy as a strategy for the treatment of non-small-cell lung cancer Therapy 8 2011 43 54
10. K.I. Al-Shibli, T. Donnem, and S. Al-Saad Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer Clin Cancer Res 14 2008 5220 5227
11. K. Hiraoka, M. Miyamoto, and Y. Cho Concurrent infiltration by CD8+T cells and CD4+T cells is a favourable prognostic factor in non-small-cell lung carcinoma Br J Cancer 94 2006 275 280
12. M.-C. Dieu-Nosjean, M. Antoine, and C. Danel Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures J Clin Oncol 26 2008 4410 4417
13. O. Kawai, G. Ishii, and K. Kubota Predominant infiltration of macrophages and CD8+T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer Cancer 113 2008 1387 1395
14. D. Miotto, N.L. Cascio, and M. Stendardo CD8+T cells expressing IL-10 are associated with a favourable prognosis in lung cancer Lung Cancer 69 2010 355 360
15. X. Zhuang, X. Xia, and C. Wang A high number of CD8+T cells infiltrated in NSCLC tissues is associated with a favorable prognosis Appl Immunohistochem Mol Morphol 18 2010 24 28
16. K. Koyama, H. Kagamu, and S. Miura Reciprocal CD4+T-cell balance of effector CD62Llow CD4+and CD62LhighCD25+CD4+regulatory T cells in small cell lung cancer reflects disease stage Clin Cancer Res 14 2008 6770 6779
17. K.N.M. Shimizu, Y. Hirami, T. Yukawa, A. Maeda, and K. Tanemoto Tumor-infiltrating Foxp3+regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer J Thorac Oncol 5 2010 585 590
18. K. Kadota, J.I. Nitadori, and P.S. Adusumilli Prognostic value of the immune microenvironment in lung adenocarcinoma Oncoimmunology 2 2013 e24036
19. A.M. Lesokhin, T.M. Hohl, and S. Kitano Monocytic CCR2+myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment Cancer Res 72 4 2012 876 886
20. S. Nagaraj, J.-I. Youn, and D.I. Gabrilovich Reciprocal relationship between myeloid-derived suppressor cells and T cells J Immunol 191 2013 17 23
21. E.Y. Woo, H. Yeh, and C.S. Chu Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation J Immunol 168 2002 4272 4276
22. M.R. Jadus, J. Natividad, and A. Mai Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention Clin Dev Immunol 2012 2012 160724
23. A.J. Marrogi, W.D. Travis, and J.A. Welsh Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma Clin Cancer Res 6 2000 4739 4744
24. Z. Yao, S. Fenoglio, and D.C. Gao TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer Proc Natl Acad Sci U S A 107 2010 15535 15540
25. Y.-C. Wang, W.-W. Sung, and T.-C. Wu Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer PLoS One 7 2012 e39525
26. F. Baratelli, J.M. Lee, and S. Hazra PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2 2010 356 367
27. N. Ramnath, D. Tan, and Q. Li Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 55 2006 891 899
28. S. Derniame, J.M. Vignaud, G.C. Faure, and M.C. Béné Alteration of the immunological synapse in lung cancer: a microenvironmental approach Clin Exp Immunol 154 1 2008 48 55
29. R.L. Jansen, R. Slingerland, and S.H. Goey Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer J Immunother 12 1992 70 73
30. S. Murala, V. Alli, and D. Kreisel Current status of immunotherapy for the treatment of lung cancer J Thorac Dis 2 2011 237 244
31. R.J. Kelly, and G. Giaccone Lung cancer vaccines Cancer J 17 2011 302 308
32. C. Butts, M. Socinski, and P. Mitchell START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 7500
33. G. Giaccone, L. Bazhenova, and J. Neumaitis A phase III study of belagenpumatucel-L therapeutic tumour cell vaccine for non-small cell lung cancer (NSCLC) Eur J Cancer (Meeting Abstracts) 49 suppl 3 2013 2
34. J. Nemunaitis, R.O. Dillman, and P.O. Schwarzenberger Phase II study of belagenpumatucel-l, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 2006 4721 4730
35. E. Vansteenkiste, M. Zielinski, and A. Linder Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results [abstract] J Clin Oncol (Meeting Abstracts) 43 2013 7103
36. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
37. L. Li, Q.G. Chao, and L.Z. Ping The prevalence of FOXP3+regulatory T-cells in peripheral blood of patients with NSCLC Cancer Biother Radiopharm 24 2009 357 367
38. E.M. Gabriel, and E.C. Lattime Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res 13 2007 785 788
39. N. Erfani, S.M. Mehrabadi, and M.A. Ghayumi Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC) Lung Cancer 77 2012 306 311
40. M.J. Butte, M.E. Keir, and T.B. Phamduy Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 2007 111 122
41. S.C. Liang, Y.E. Latchman, and J.E. Buhlmann Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses Eur J Immunol 33 2003 2706 2716
42. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 8 2008 467 477
43. K. Pfistershammer, C. Klauser, and W.F. Pickl No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation Eur J Immunol 36 2006 1104 1113
44. C.-Y. Mu, J.-A. Huang, and Y. Chen High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 2011 682 688
45. Y.B. Chen, C.Y. Mu, and J.A. Huang Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study Tumori 98 2012 751 755
46. H. Dong, S.E. Strome, and D.R. Salomao Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
47. J. Konishi, K. Yamazaki, and M. Azuma B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 2004 5094 5100
48. A. Rosenwald, G. Wright, and K. Leroy Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma J Exp Med 198 2003 851 862
49. Y. Zhang, L. Wang, and Y. Li Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma Onco Targets Ther 7 2014 567 573
50. R. Hino, K. Kabashima, and Y. Kato Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 116 2010 1757 1766
51. P. Carrega, B. Morandi, and R. Costa Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16-cells and display an impaired capability to kill tumor cells Cancer 112 2008 863 875
52. A. Wis̈niewski, R. Jankowska, and E. Passowicz-Muszyńska KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population Human Immunol 73 2012 927 931
53. J. Matsuzaki, S. Gnjatic, and P. Mhawech-Fauceglia Tumor-infiltrating NY-ESO-1-specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer Proc Natl Acad Sci U.S.A 107 2010 7875 7880
54. J.F. Grosso, C.C. Kelleher, and T.J. Harris LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems J Clin Invest 117 2007 3383 3392
55. S. Sierro, P. Romero, and D.E. Speiser The CD4-like molecule LAG-3, biology and therapeutic applications Expert Opin Ther Targets 15 2011 91 101
56. S.-R. Woo, M.E. Turnis, and M.V. Goldberg Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 72 2012 917 927
57. D. Schadendorf, F.S. Hodi, and C. Robert Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract] Eur J Cancer (Meeting Abstracts) 49 Suppl 2 2013 24LBA
58. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
59. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
60. M. Maio, I. Bondarenko, and C. Robert Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma [abstract] Eur J Cancer (Meeting Abstracts) 49 Suppl 2 2013 3704
61. C. Lebbe, J.S. Weber, and M. Maio Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials [abstract] J Clin Oncol (Meeting Abstracts) 31 Suppl 1 2013 9053
62. A.M. Di Giacomo, L. Calabrò, and R. Danielli Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme Cancer Immunol Immunother 62 2013 1021 1028
63. T.J. Lynch, I. Bondarenko, and A. Luft Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
64. H. Liu, T. Zhang, and J. Ye Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer Cancer Immunol Immunother 61 2012 1849 1856
65. Nokihara H. Phase 1 study of ipilimumab in combination with paclitaxel/carboplatin in patients with non-small cell lung cancer. In IASLC 15th World Conference on Lung Cancer. 2013, P2. 11-040: Sydney, Australia.
66. M. Reck, I. Bondarenko, and A. Luft Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
67. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
68. Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results [abstract]. J Clin Oncol (Meeting Abstracts). 2014;32(Suppl 5s):8023.
69. P. Zatloukal, D.S. Heo, and K. Park Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 27 Suppl 2009 8071
70. L. Calabrò, A. Morra, and E. Fonsatti Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial Lancet Oncol 14 2013 1104 1111
71. L. Calabrò, A. Morra, and E. Fonsatti A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 7531
72. M. Maio, A. Scherpereel, and A. Di Pietro Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 TPS7609
73. J.R. Brahmer, L. Horn, and L. Gandhi Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 8112
74. S.N. Gettinger, F.A. Shepherd, and S.J. Antonia First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 8024
75. D.P. Carbone, M.A. Socinski, A.C. Chen, P. Bhagavatheeswaran, M. Reck, and L. Paz-Ares A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 TPS8128
76. N.A. Rizvi, L.Q.M. Chow, and H. Borghaei Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 8022
77. N. Rizvi, S.J. Antonia, and L.Q.M. Chow A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts) [abstract] J Clin Oncol (Meeting Abstracts) 31 Suppl 2013 8072
78. A. Patnaik, S.P. Kang, and A.W. Tolcher Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors [abstract] J Clin Oncol (Meeting Abstracts) 30 Suppl 2012 2512
79. E.B. Garon, A. Balmanoukian, and O. Hamid MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity [abstract] Clin Cancer Res (Meeting Abstracts) 20 2014 A20
80. N.A. Rizvi, E.B. Garon, and A. Patnaik Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 8007
81. F. Smothers, A. Hoos, and S. Langermann AMP-224, a fusion protein that targets PD-1 Ann Oncol 24 2013 i7
82. D. Spigel, N.G. Scott, and L. Horn Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 31 Suppl 2013 8008
83. Horn L, Herbst R, Spiegel D. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPD-L3280A (anti-PDL1). In IASLC 14th World Conference on Lung Cancer. 2012, MO18.01: Amsterdam, the Netherlands.
84. R.S. Herbst, M.S. Gordon, and G.D. Fine A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors [abstract] J Clin Oncol (Meeting Abstracts) 31 Suppl 2013 3000
85. Soria J. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). European Cancer Congress 2013. Amsterdam, the Netherlands, 2013.
86. N.A. Rizvi, L.Q.M. Chow, and L.Y. Dirix Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 TPS8123
87. Khlief SL, Segal NH, et al. MEDI4736, an anti-PD-L1 antibody with engineered Fc domain preclinical evaluation and early clinical results from a Phase I study in patients with advanced solid tumors. In European Cancer Congress, 2013. Amsterdam, the Netherlands, 2013.
88. J.R. Brahmer, N.A. Rizvi, and J. Lutzky Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC [abstract] J Clin Oncol (Meeting Abstracts) 32 Suppl 5s 2014 8021
89. J.R. Brahmer, S.S. Tykodi, and L.Q.M. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
90. R.E. Sanborn, W.H. Sharfman, and N.H. Segal A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors [abstract] J Clin Oncol (Meeting Abstracts) 31 Suppl 2013 TPS3110
91. A. Wang-Gillam, S. Plambeck-Suess, and P. Goedegebuure A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma Invest New Drugs 31 2013 707 713
92. C. Brignone, B. Escudier, and C. Grygar A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma Clin Cancer Res 15 2009 6225 6231
93. C. Brignone, M. Gutierrez, and F. Mefti First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG3Ig) enhances immune responses and antitumour activity J Transl Med 8 2010 71
94. K. Garber Beyond ipilimumab: new approaches target the immunological synapse J Natl Cancer Inst 103 2011 1079 1082
95. R.H. Vonderheide, K.T. Flaherty, and M. Khalil Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody J Clin Oncol 25 2007 876 883
96. R.H. Vonderheide, J.M. Burg, and R. Mick Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors Oncoimmunology 2 1 2013 e23033
97. P.W. Johnson, N.M. Steven, and Chowdhury A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4 [abstract] J Clin Oncol (Meeting Abstracts) 28 Suppl 2010 2507
98. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
99. J.F. Grosso, C.E. Horak, and H.D. Inzunza Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract] J Clin Oncol (Meeting Abstracts) 31 Suppl 2013 3016
100. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
101. M.B. Freidin, N. Bhudia, and E. Lim Impact of collection and storage of lung tumor tissue on whole genome expression profiling J Mol Diagn 14 2 2012 140 148
102. E.J. Lipson, W.H. Sharfman, and C.G. Drake Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 2013 462 468
103. C. Robert, D. Schadendorf, and M. Messina Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control Clin Cancer Res 19 2013 2232 2239